786.347.3500
info@demerx.com
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the launch of a Phase I/IIa trial of DemeRx and atai Life Sciences’ ibogaine HCl (DMX-1002) for the treatment of opioid use disorder (OUD). The approval will enable DemeRx to evaluate ibogaine HCl in......
11 March, 2021NEW YORK, March 10, 2021 /PRNewswire/ — DemeRx IB, Inc. (DemeRx), an atai Life Sciences (atai) platform company focused on developing ibogaine for the treatment of opioid use disorder (OUD), today announced the company has approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to commence......
11 March, 2021A joint venture between DemeRx and Atai Life Sciences has been cleared by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to start enrolment for a Phase I/IIa trial of ibogaine HCl (DMX-1002) in the treatment of opioid use disorder (OUD). A joint venture......
11 March, 2021People seeking treatment to overcome opioid addiction are often stymied by the treatment itself. Many don’t have access to drugs like methadone or buprenorphine or can’t make it to a clinic every day for a long enough time for the treatment to succeed. ATAI Life......
24 January, 2020BERLIN and MIAMI, Jan. 24, 2020 /PRNewswire/ — ATAI Life Sciences AG (“ATAI” or the “Company”), a global biotech platform that envisions an end to mental illnesses, today announced an investment in two separate joint ventures (JV) with DemeRx, a clinical stage pharmaceutical company focused on developing ibogaine and noribogaine for the......
24 January, 2020INTERNATIONAL – The World Economic Forum’s billionaire audience in Davos took a break from the problem of climate change to listen to the story of a company developing a hallucinogenic drug. The fascination lay not in recreation, but for its potential as a treatment for......
24 January, 2020